Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
Healthcare
$42.53 -1.86%
-$0.62 today
- Market cap
- $800.84M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
52W Low $18.14High $52.24
Volume 0.24M
Average 0.36M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$75.66M
FY 2025 · Annual
+140.4% YoYInvesting Cash Flow
-$92.36M
FY 2025 · Annual
Financing Cash Flow
$601,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (245.85M) |
| Stock-Based Compensation | 9.49M | 12.39M | 8.81M | 12.39M | 12.71M |
| Change in Working Capital | 9.72M | (29.05M) | 9.52M | 153K | (19.51M) |
| Accounts Receivables | 501K | (24.85M) | 9.77M | (11.07M) | (10.15M) |
| Inventory | (4.88M) | (2.38M) | 1.17M | 764K | (5.64M) |
| Accounts Payables | 41K | 3.79M | (366K) | (3.8M) | 3.85M |
| Other Working Capital | 14.05M | (5.61M) | (1.06M) | 14.26M | (7.58M) |
| Other Non-Cash Items | 3.43M | 481K | (213K) | (788K) | (41.13M) |
| Operating Cash Flow | 5.88M | (73.76M) | (5.74M) | 31.47M | 75.66M |
| Capital Expenditures | (627K) | (450K) | (15M) | (396K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (141.46M) | (28.89M) | (31.21M) | (35.27M) | (153.49M) |
| Sales of Investments | 62.05M | 101.23M | 41.65M | 39.7M | 61.13M |
| Other Investing Activities | 0 | 893K | 259K | 98K | 0 |
| Investing Cash Flow | (80.04M) | 72.78M | (4.3M) | 4.13M | (92.37M) |
| Debt Repayment | 0 | 19.54M | 19.95M | 0 | (7.5M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 8.1M |
| Common Stock Repurchased | 0 | 0 | 0 | (10M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 62.68M | (12.99M) | (1.58M) | (1.64M) | 0 |
| Financing Cash Flow | 62.68M | 6.55M | 18.37M | (11.64M) | 601K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.48M) | 5.57M | 8.33M | 23.96M | (16.11M) |
| Free Cash Flow | 5.25M | (74.21M) | (20.74M) | 31.08M | 75.66M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$367.0M
+ D&A$2.4M
+ Stock-Based Comp$12.7M
- Deferred Tax-$245.9M
- Working Capital-$19.5M
- Other Non-Cash-$41.1M
= Operating Cash Flow$75.7M
- Capex$0
= Free Cash Flow$75.7M
Analysis
FY2025 free cash flow is $75.7M. FCF conversion is 20.6% of net income. Operating cash flow was $75.7M, with capex of $0. The largest bridge item is Deferred Tax at -$245.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 3, 2026 |
Does RIGL generate free cash flow?
Rigel Pharmaceuticals, Inc. (RIGL) generated $75.66M of free cash flow in fiscal 2025.
How much operating cash flow does RIGL produce?
Operating cash flow was $75.66M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.